Skip to main content

Dare Bioscience Inc

For the period ended Dec 31, 2023. Filed Mar 28, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 28, 2024

DARE$0.68+6.4%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Daré Bioscience, Inc.
By:/s/ SABRINA MARTUCCI JOHNSON
Date: March 28, 2024President and Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

SignatureTitleDate
/s/ SABRINA MARTUCCI JOHNSONPresident and Chief Executive Officer(Principal Executive Officer and Principal Financial Officer) and DirectorMarch 28, 2024
Sabrina Martucci Johnson
/s/ MARDEE HARING-LAYTONChief Accounting OfficerMarch 28, 2024
MarDee Haring-Layton(Principal Accounting Officer)
/s/ WILLIAM H. RASTETTERChairman of the Board and DirectorMarch 28, 2024
William H. Rastetter, Ph.D.
/s/ CHERYL R. BLANCHARDDirectorMarch 28, 2024
Cheryl R. Blanchard, Ph.D.
/s/ JESSICA D. GROSSMANDirectorMarch 28, 2024
Jessica D. Grossman, M.D.
/s/ SUSAN L. KELLEYDirectorMarch 28, 2024
Susan L. Kelley, M.D.
/s/ GREGORY W. MATZDirectorMarch 28, 2024
Gregory W. Matz, CPA
/s/ SOPHIA ONONYE-ONYIADirectorMarch 28, 2024
Sophia Ononye-Onyia, Ph.D.
/s/ ROBIN STEELEDirectorMarch 28, 2024
Robin Steele, J.D., L.L.M.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.